Popular GLP-1 medications approved for weight loss, diabetes, and heart disease may have untapped potential to treat ...
In one corner, we’ve got Mounjaro, and in the other, Ozempic. They’re both once-a-week injectable drugs designed to help ...
People who stayed on a 7.2 milligram weekly dose of semaglutide lost around 20% of their body weight over 72 weeks.
Ozempic and similar drugs are advertised all over the place, from television ads, public transit, audio streaming platforms ...
Over 2 million people were included in new research to test these drugs against 175 different health outcomes.
An observational study has uncovered a possible link between taking GLP-1s and increased risk of kidney, pancreas and gut ...
The study included nearly 2 million patients, making it the largest ever conducted on this group of glucagon-like peptide-1 ...
Elon Musk, the CEO of Tesla and SpaceX, has been candid about his struggle with weight loss. The billionaire has openly ...